Rigel Hires Alison Hannah as Chief Medical Officer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Rigel Pharmaceuticals hired Alison Hannah as executive vice president and chief medical officer, its top clinical leadership role.
- Alison Hannah previously held the identical CMO position at CytomX Therapeutics, making this a direct lateral transition into the same seat rather than a step up from a lower role.
- STAT's recurring "Up and down the ladder" column spotlights a single personnel move each week and openly invites companies to submit their own hires, promotions, and departures for future editions.
- The full announcement sits behind the STAT+ paywall, positioning what is essentially a one-paragraph personnel blurb as premium content for industry subscribers.
Why it matters: A direct lateral CMO move from CytomX to Rigel means the incoming chief medical officer arrives already seasoned in the role rather than stepping up from a lower position, shortening any on-ramp for Rigel's clinical pipeline decisions. For STAT+ readers tracking executive churn, this week's highlighted move underscores continued lateral turnover among chief medical officers across the biopharma sector.